Add-on therapy with angiotensin II receptor 1 blocker in children with chronic kidney disease already treated with angiotensin-converting enzyme inhibitors

Pediatric Nephrology

Volumn 21, Issue 11, 2006, Pages 1716-1722

  Litwin, Mieczysław ^a   Grenda, Ryszard ^a   Śladowska, Joanna ^a   Antoniewicz, Jolanta ^a  

^a CHILDREN'S MEMORIAL HEALTH INSTITUTE   (Poland)

Author keywords

Angiotensin II receptor 1 blockers; Angiotensin converting enzyme inhibitors; Arterial hypertension; Children; Chronic kidney disease progression; Losartan; Renoprotection

Indexed keywords

ACEBUTOLOL; ALDOSTERONE; AMLODIPINE; ANGIOTENSIN; ANGIOTENSIN RECEPTOR ANTAGONIST; ATENOLOL; CAPTOPRIL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DOXAZOSIN; ENALAPRIL; FUROSEMIDE; LABETALOL; LOSARTAN; NIFEDIPINE; POTASSIUM; RAMIPRIL; RENIN; SPIRONOLACTONE; VERAPAMIL;

ADD ON THERAPY; ADOLESCENT; ADULT; ARTICLE; BLOOD PRESSURE REGULATION; CHILD; CHRONIC KIDNEY DISEASE; CLINICAL ARTICLE; CONGENITAL NEPHROTIC SYNDROME; CONTROLLED STUDY; COUGHING; DIASTOLIC BLOOD PRESSURE; DOSE RESPONSE; DRUG EFFICACY; DRUG ERUPTION; DRUG SAFETY; FEMALE; GLOMERULUS FILTRATION RATE; HEMOLYTIC UREMIC SYNDROME; HUMAN; HYPERKALEMIA; HYPERTENSION; INFANT; KIDNEY CORTEX NECROSIS; KIDNEY FAILURE; MALE; PRIORITY JOURNAL; PROTEINURIA; PRUNE BELLY SYNDROME; REFLUX NEPHROPATHY; RENAL PROTECTION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; SYSTOLIC BLOOD PRESSURE; TREATMENT DURATION; TREATMENT OUTCOME;

ADOLESCENT; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; BLOOD PRESSURE; CHILD; CHILD, PRESCHOOL; CHRONIC DISEASE; DISEASE PROGRESSION; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; INFANT; KIDNEY DISEASES; MALE;

EID: 33748695980     PISSN: 0931041X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00467-006-0223-2     Document Type: Article

References (23)

1. Del Vecchio L, Locatelli F (2001) The renoprotective effect of combined antihypertensive drugs. J Nephrol 14:7-14
2. Lama G, Salsano ME, Pedulla M, Grassia C, Ruocco G (1997) Angiotensin converting enzyme inhibitors and reflux nephropathy: A 2-year follow-up. Pediatr Nephrol 11:714-718
3. Trachtman H, Gauthier B (1988) Effect of angiotensin-converting enzyme inhibitor therapy on proteinuria in children with renal disease. J Pediatr 112:295-298
4. Ruilope LM, Aldigier JC, Ponticelli C, Oddou-Stock P, Botteri F, Mann JF (2000) Safety of the combination of valsartan and benazepril in patients with chronic renal disease. European Group for the Investigation of Valsartan in Chronic Renal Disease. J Hypertens 18:89-95
5. Nakao N, Seno H, Kasuga H, Toriyama T, Kawahara H, Fukagawa M (2004) Effects of combination treatment with losartan and trandolapril on office and ambulatory blood pressures in non-diabetic renal disease: A COOPERATE-ABP substudy. Am J Nephrol 24:543-548
6. Nakao N, Yoshimura A, Morita H, Takada M, Kayano T, Ideura T (2003) Combination treatment of angiotensin-II receptor blocker and angiotensin-converting-enzyme inhibitor in non-diabetic renal disease (COOPERATE): A randomised controlled trial. Lancet 361:117-124
7. Shiigai T, Schichiri M (2001) Late escape from the antiproteinuric effect of ACE inhibitors in nondiabetic renal disease. Am J Kid Dis 37:477-483
8. Kincaid-Smith P, Fairley KF, Packham D (2004) Dual blockade of the renin-angiotensin system compared with a 50% increase in the dose of angiotensin-converting enzyme inhibitor: Effects on proteinuria and blood pressure. Nephrol Dial Transplant 19:2272-2274
9. National High Blood Pressure Education Program Working Group on High Blood Pressure in Children and Adolescents (2004) The fourth report on the diagnosis, evaluation and treatment of high blood pressure in children and adolescents. Pediatrics 114:555-576
10. Wuhl E, Mehls O, Schaefer F; ESCAPE Trial Group (2004) Antihypertensive and antiproteinuric efficacy of ramipril in children with chronic renal failure. Kidney Int 66:768-776
11. Van Dyck M, Proesmans W (2004) Renoprotection by ACE inhibitors after severe hemolytic uremic syndrome. Pediatr Nephrol 19:688-690
12. Litwin M (2004) Risk factors for renal failure in children with non-glomerular nephropathies. Pediatr Nephrol 19:178-186
13. Adler L, Mathew R, Futterweit S, Frank R, Gauthier BG, Kashtan CE, Trachtman H (2002) Angiotensin converting enzyme inhibitor therapy in children with Alport syndrome: Effect on urinary albumin, TGF-beta and nitrite excretion. BMC Nephrol 3:2
14. Holmberg C, Trygvasson K, Kestila MK, Jalanko HJ (2004) Congenital nephrotic syndrome. In: Avner ED, Harmon WE, Niaudet P (eds) Pediatric nephrology, 5th edn. Lippincot Wiliams & Wilkins, pp 503-516
15. Hamed RM, Shomaf M (2002) Congenital nephritic syndrome: A clinico-pathological study of 30 children. J Nephrol 14:104-109
16. Ellis D, Moritz ML, Vats A, Janosky JE (2004) Antihypertensive and renoprotective efficacy and safety of losartan. A long-term study in children with renal disorders. Am J Hypertens 17:928-935
17. Gartenmann AC, Fossali E, von Vigier RO, Simonetti GD, Schmidtko J, Edefonti A, Bianchetti MG (2003) Better renoprotective effect of angiotensin II antagonist compared to dihydropyridine calcium channel blocker in childhood. Kidney Int 64:1450-1454
18. Tanaka H, Suzuki K, Nakahata T, Tsugawa K, Konno Y, Tsuruga K, Ito E, Waga S (2004) Combined therapy of enalapril and losartan attenuates histologic progression in immunoglobulin A nephropathy. Pediatr Int 46:576-579
19. Yang Y, Ohta K, Shimizu M, Nakai A, Kasahara Y, Yachie A, Koizumi S (2005) Treatment with low-dose angiotensin-converting enzyme inhibitor (ACEI) plus angiotensin II receptor blocker (ARB) in pediatric patients with IgA nephropathy. Clin Nephrol 64:35-40
20. Ihle BU, Whitwirth JA, Shahinfar S, Cnaan A, Kincaid-Smith PS, Becker GJ (1996) Angiotensin-converting enzyme inhibition in non-diabetic progressive renal insufficiency: A controlled double-blind trial. Am J Kidney Dis 27:489-495
21. Hou FF, Zhang X, Zhang GH, Xie D, Chen PY, Zhang WR, Jiang JP, Liang M, Wang GB, Liu ZR, Gang RW (2006) Efficacy and safety of benazepril for advanced chronic renal insufficiency. N Eng J Med 354:131-140
22. Shahinfar S, Cano F, Sofffer BA, Ahmed T, Santoro EP, Zhang Z, Gleim G, Miller K, Vogt B, Blumer J, Biezogounov J (2005) A double-blind, dose-response study of losartan in hypertensive children. Am J Hypertens 18:183-190
23. Rossing K, Schjoedt KJ, Jensen BR, Boomsma F, Parving HH (2005) Enhanced renoprotective effects of ultrahigh doses of irbesartan in patients with type 2 diabetes and microalbuminuria. Kidney Int 68:1190-1198